Use of marizomib for the treatment of central nervous system (CNS) cancers
US11980606B2 · kind B2 · utility
0Cited by
12References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2020 |
| Grant date | May 14, 2024 |
| Priority date | — |
| Expiry date | Nov 7, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to treatment of central nervous system (CNS) cancers (e.g., malignant glioma, glioblastoma, or CNS-multiple myeloma) using marizomib. The disclosure further relates to uses of synergistic combinations of marizomib with additional therapeutic agents such as bevacizumab, daratumumab, temozolomide, pomalidomide, and radiotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.